Consilience in sarcopenia of cirrhosis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Cirrhosis is the consequence of progression of many forms of necro‐inflammatory disorders of the liver with hepatic fibrosis, hepatocellular dysfunction, and vascular remodeling. Reversing the primary hepatic disorder, liver transplantation, and controlling the complications are the major management goals. Since the former options are not available to the majority of cirrhotics, treating complications remains the mainstay of therapy. Sarcopenia and/or cachexia is the most common complication and adversely affects survival, quality of life, development of other complications of cirrhosis, and outcome after liver transplantation. With the increase in number of cirrhotic patients with hepatitis C and nonalcoholic fatty liver disease, the number of patients waiting for a liver transplantation is likely to continue to increase above the currently estimated 72.3/100,000 population. One of the critical clinical questions is to determine if we can treat sarcopenia of cirrhosis without transplantation. No effective therapies exist to treat sarcopenia because the mechanism(s) of sarcopenia in cirrhosis is as yet unknown. The reasons for this include the predominantly descriptive studies to date and the advances in our understanding of skeletal muscle biology and molecular regulation of atrophy and hypertrophy not being translated into the clinical practice of hepatology. Satellite cell biology, muscle autophagy and apoptosis, and molecular signaling abnormalities in the skeletal muscle of cirrhotics are also not known. Aging of the cirrhotic and transplanted population, use of mTOR inhibitors, and the lack of definitive outcome measures to define sarcopenia and cachexia in this population add to the difficulty in increasing our understanding of hepatic sarcopenia/cachexia and developing treatment options. Recent data on the role of myostatin, AMP kinase, impaired mTOR signaling resulting in anabolic resistance in animal models, and the rapidly developing field of nutriceuticals as signaling molecules need to be evaluated in human cirrhotics. Finally, the benefits of exercise reported in other disease states with sarcopenia may not be safe in cirrhotics due to the risk of gastrointestinal variceal bleeding due to an increase in portal pressure. This article focuses on the problems facing both muscle biologists and hepatologists in developing a comprehensive approach to sarcopenia in cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. F., & Bell, B. P. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.013 · Cited by 2,572
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
Watanabe, M., Houten, S. M., Mataki, C., Christoffolete, M. A., Kim, B. W., Sato, H., Messaddeq, N., Harney, J. W., Ezaki, O., Kodama, T., et al. (2006) · Nature · doi:10.1038/nature04330 · Cited by 2,220 · cited 1×
“Bile salts have been reported to increase muscle oxygen consumption and energy expenditure [87].”
BackgroundInvited Review: Aging and sarcopenia
Doherty, T. J. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00347.2003 · Cited by 1,764 · cited 1×
“It is well recognized that the skeletal muscle mass in humans increases till the age of 20, is stable between 20 and 50, and after the age of 50 years, there is approximately a 1 % loss of muscle mass [69, 70].”
BackgroundMuscaritoli, M., Anker, S. D., Argilés, J., Aversa, Z., Bauer, J. M., Biolo, G., Boirie, Y., Bosaeus, I., Cederholm, T., Costelli, P., et al. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2009.12.004 · Cited by 1,732
Sarcopenia with limited mobility: an international consensus
Morley, J. E., Abbatecola, A. M., Argiles, J. M., Baracos, V., Bauer, J., Bhasin, S., Cederholm, T., Stewart Coats, A. J., Cummings, S. R., Evans, W. J., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.04.014 · Cited by 1,125
Katsanos, C. S., Kobayashi, H., Sheffield-Moore, M., Aarsland, A., & Wolfe, R. R. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00488.2005 · Cited by 923 · cited 1×
“However, since sarcopenia in cirrhosis as in other conditions with anabolic resistance is believed to be due to impaired mTOR signaling response, it can potentially be overcome by leucine-enriched supplementation with amino acids [124–126].”
BackgroundAn overview of sarcopenia: facts and numbers on prevalence and clinical impact
von Haehling, S., Morley, J. E., & Anker, S. D. (2010) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1007/s13539-010-0014-2 · Cited by 888
Kumar, V., Selby, A., Rankin, D., Patel, R., Atherton, P., Hildebrandt, W., Williams, J., Smith, K., Seynnes, O., Hiscock, N., et al. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2008.164483 · Cited by 740 · cited 1×
“limited the translation of the data or the elegant designs of the studies performed in noncirrhotic patients [136–143].”
Muscle strength and body mass index as long-term predictors of mortality in initially healthy men
Rantanen, T., Harris, T., Leveille, S. G., Visser, M., Foley, D., Masaki, K., & Guralnik, J. M. (2000) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/55.3.m168 · Cited by 647 · cited 1×
“Since skeletal muscle mass and strength have been related to survival and quality of life in cirrhosis as well as other chronic disorders with sarcopenia, studies that focus on such definite measures are necessary [24, 25, 83, 106, 107].”
BackgroundHartman, J. W., Tang, J. E., Wilkinson, S. B., Tarnopolsky, M. A., Lawrence, R. L., Fullerton, A. V., & Phillips, S. M. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.2.373 · Cited by 498
Bohé, J., Low, A., Wolfe, R. R., & Rennie, M. J. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.050674 · Cited by 496 · cited 3×
“Extracellular rather than intracellular concentrations of amino acids have been shown to be potent regulators of muscle protein metabolic response [82].”
BackgroundDreyer, H. C., Drummond, M. J., Pennings, B., Fujita, S., Glynn, E. L., Chinkes, D. L., Dhanani, S., Volpi, E., & Rasmussen, B. B. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00582.2007 · Cited by 447 · cited 1×
“Use of leucine-enriched essential amino acids to stimulate mTOR independent of upstream inhibitors including myostatin and AMPK has been shown to be effective in other disorders with muscle atrophy [113–115].”
BackgroundDrummond, M. J., Fry, C. S., Glynn, E. L., Dreyer, H. C., Dhanani, S., Timmerman, K. L., Volpi, E., & Rasmussen, B. B. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2008.163816 · Cited by 439 · cited 1×
“data on sarcopenia in aging and molecular mechanisms of regulation of muscle loss and re-growth [30, 48–54].”
BackgroundBurd, N. A., Tang, J. E., Moore, D. R., & Phillips, S. M. (2009) · Journal of Applied Physiology · doi:10.1152/japplphysiol.91351.2008 · Cited by 390 · cited 1×
“Finally, the source of dietary proteins, the amino acid composition as well as the digestibility of different proteins and the age of the subject alter the muscle protein metabolic response [112, 133, 134].”
BackgroundAging, exercise, and muscle protein metabolism
Koopman, R., & van Loon, L. J. C. (2009) · Journal of Applied Physiology · doi:10.1152/japplphysiol.91551.2008 · Cited by 371
Aging impairs contraction-induced human skeletal muscle mtorc1 signaling and protein synthesis
Fry, C. S., Drummond, M. J., Glynn, E. L., Dickinson, J. M., Gundermann, D. M., Timmerman, K. L., Walker, D. K., Dhanani, S., Volpi, E., & Rasmussen, B. B. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-11 · Cited by 351
Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis
Owen, O. E., Reichle, F. A., Mozzoli, M. A., Kreulen, T., Patel, M. S., Elfenbein, I. B., Golsorkhi, M., Chang, K. H., Rao, N. S., Sue, H. S., et al. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110240 · Cited by 290 · cited 1×
“These include dysregulation of fatty acid oxidation and ketogenesis, gluconeogenesis from amino acids, glycogenolysis, and selective utilization of aromatic amino acids in the liver and branched chain amino acids in the skeletal muscle as a source of energy [27, 28].”
BackgroundDickinson, J. M., Fry, C. S., Drummond, M. J., Gundermann, D. M., Walker, D. K., Glynn, E. L., Timmerman, K. L., Dhanani, S., Volpi, E., & Rasmussen, B. B. (2011) · The Journal of Nutrition · doi:10.3945/jn.111.139485 · Cited by 282 · cited 1×
“Identification of mTOR regulation by nutrient sensor, AMP kinase, general control of nutrition derepressed (GCN2) as a leucine sensor, and identification of increased skeletal muscle autophagy as a potential contributor to loss of muscle mass as well as its protective role during nutrient starvation are very exciting…”
BackgroundDrummond, M. J., & Rasmussen, B. B. (2008) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e3282fa17fb · Cited by 274 · cited 1×
“Use of leucine-enriched essential amino acids to stimulate mTOR independent of upstream inhibitors including myostatin and AMPK has been shown to be effective in other disorders with muscle atrophy [113–115].”
BackgroundIncreased perioperative mortality following bariatric surgery among patients with cirrhosis
Mosko, J. D., & Nguyen, G. C. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.07.007 · Cited by 266
Late evening snack: exploiting a period of anabolic opportunity in cirrhosis
Tsien, C. D., McCullough, A. J., & Dasarathy, S. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06951.x · Cited by 252
Phillips, S. M., Tang, J. E., & Moore, D. R. (2009) · Journal of the American College of Nutrition · doi:10.1080/07315724.2009.10718096 · Cited by 243
Quantitation of "autophagic flux" in mature skeletal muscle
Ju, J.-S., Varadhachary, A. S., Miller, S. E., & Weihl, C. C. (2010) · Autophagy · doi:10.4161/auto.6.7.12785 · Cited by 229 · cited 1×
“Our recent preliminary data that an increase in muscle mass [55, 56] is likely to improve survival provides an impetus for rapid translation to clinical use of many of the novel concepts in skeletal muscle loss including the role of satellite cells, autophagy, myostatin regulation of muscle mass, proteolytic pathways,…”
BackgroundSkeletal muscle dysfunction in patients with chronic obstructive pulmonary disease
Hussain, S., Cheol, K., & Mofarrahi, M. (2008) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s4480 · Cited by 224 · cited 1×
“In contrast to the sarcopenia of cirrhosis, other systemic disorders and aging are also accompanied by sarcopenia with consequent reduced survival and quality of life (Table 2) [70, 90–102].”
BackgroundGlynn, E. L., Fry, C. S., Drummond, M. J., Timmerman, K. L., Dhanani, S., Volpi, E., & Rasmussen, B. B. (2010) · The Journal of Nutrition · doi:10.3945/jn.110.127647 · Cited by 194
Branched-Chain Amino Acids as Fuels and Anabolic Signals in HumanMuscle
Rennie, M. J., Bohé, J., Smith, K., Wackerhage, H., & Greenhaff, P. (2006) · The Journal of Nutrition · doi:10.1093/jn/136.1.264s · Cited by 185 · cited 1×
“Therefore, administration of the appropriate combination of essential amino acids to alter plasma concentrations can be an effective therapy in these patients [82, 130].”
BackgroundMaximizing muscle protein anabolism: the role of protein quality
Tang, J. E., & Phillips, S. M. (2009) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32831cef75 · Cited by 178 · cited 1×
“Finally, the source of dietary proteins, the amino acid composition as well as the digestibility of different proteins and the age of the subject alter the muscle protein metabolic response [112, 133, 134].”
BackgroundSarcopenia: prevalence, mechanisms, and functional consequences
Berger, M. J., & Doherty, T. J. (2010) · Interdisciplinary topics in gerontology and geriatrics · doi:10.1159/000319997 · Cited by 175
Drummond, M. J., Fry, C. S., Glynn, E. L., Timmerman, K. L., Dickinson, J. M., Walker, D. K., Gundermann, D. M., Volpi, E., & Rasmussen, B. B. (2011) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01408.2010 · Cited by 120 · cited 1×
“data on sarcopenia in aging and molecular mechanisms of regulation of muscle loss and re-growth [30, 48–54].”
BackgroundKoopman, R., Verdijk, L. B., Beelen, M., Gorselink, M., Kruseman, A. N., Wagenmakers, A. J. M., Kuipers, H., & van Loon, L. J. C. (2008) · British Journal Of Nutrition · doi:10.1017/s0007114507812013 · Cited by 104 · cited 1×
“limited the translation of the data or the elegant designs of the studies performed in noncirrhotic patients [136–143].”
Method
Cited by
EASL Clinical Practice Guidelines on nutrition in chronic liver disease
Merli, M., Berzigotti, A., Zelber-Sagi, S., Dasarathy, S., Montagnese, S., Genton, L., Plauth, M., & Parés, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.024 · Cited by 1,130
Self-citationNishikawa, H., Shiraki, M., Hiramatsu, A., Moriya, K., Hino, K., & Nishiguchi, S. (2016) · Hepatology Research · doi:10.1111/hepr.12774 · Cited by 656
Sarcopenia from mechanism to diagnosis and treatment in liver disease
Dasarathy, S., & Merli, M. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.040 · Cited by 608
Self-citationHamaguchi, Y., Kaido, T., Okumura, S., Kobayashi, A., Hammad, A., Tamai, Y., Inagaki, N., & Uemoto, S. (2016) · Nutrition · doi:10.1016/j.nut.2016.04.003 · Cited by 536
Montano-Loza, A. J., Angulo, P., Meza-Junco, J., Prado, C. M. M., Sawyer, M. B., Beaumont, C., Esfandiari, N., Ma, M., & Baracos, V. E. (2016) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12039 · Cited by 512
“5) 51 (38) 131 (37) AILD 15 (7) 23 (8) 8 (6) 30 (9) HBV 18 (9) 18 (6) 8 (6) 14 (4) NASH-Cryptogenic 44 (21) 59 (20) 26 (19) 88 (25) Others 1 (0.”
Metadata
- Authors
- Dasarathy, S.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2012-05-31
- Volume
- 3
- Issue
- 4
- Pages
- 225-237
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W1991870955
- Cited by
- 247
- References
- 30
- FWCI
- 6.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.